Emerald has raised £1.4m pre-seed investment to ‘close the loop on preventive health’.

The HealthTech pairs every member with a dedicated GP who can review the personalised action plan and, where appropriate, diagnose, prescribe, and guide that person’s next steps.

It says that users build a cohesive and consistent story that moves with them – the antithesis of the fragmented system they’re used to. The journey starts with Emerald’s Baseline, a comprehensive blood test covering 115+ biomarkers, available at 50+ locations across the UK.

The round was led by Boost Capital Partners, with participation from Mark Fountain (Founder of HBS UK, acquired by AXA in 2024), Granatus Ventures, and a lineup of angel investors including Premier League footballers and successful tech founders.

The firm has also secured regulatory approvals.